Explore the Future of Addiction Recovery: Ibogaine Research Studies and Findings

Key Takeaways

• Most published ibogaine research is observational, which means researchers tracked people who had already undergone treatment on their own.
• In a 2017 survey of 88 people treated for opioid use, 80% said ibogaine eliminated or drastically reduced their withdrawal symptoms.
• A 2024 Stanford Medicine study of 30 special operations veterans reported average drops of 88% in PTSD symptoms, 87% in depression, and 81% in anxiety one month after treatment.
• Changes in heart rhythm (QT prolongation) remain a constant in the research, which is why cardiac screening and continuous monitoring matter so much.
• Large Phase III trials of ibogaine haven’t been completed yet, so current findings are promising but still early.

Most of what we know about ibogaine comes from a small but growing body of research. That research includes observational studies that follow patients for a year after treatment, detailed case reports, a handful of early-phase clinical trials, and lab work on safer synthetic versions of the compound. Together, these ibogaine research studies have looked at opioid withdrawal, veterans with brain injuries, multiple sclerosis, and the heart risks that make medical screening so important. Below, we walk through how clinical trial phases work and what the key published studies found. We also cover where the evidence is still thin, so you can read ibogaine headlines without bias. If you’re looking for the latest on FDA approval and the April 2026 Executive Order, our guide to ibogaine clinical trials and FDA status covers those updates.

What Are Ibogaine Research Studies?

Ibogaine research studies examine how safe ibogaine is and which conditions it may help treat. Some track patient outcomes for months or a full year after treatment, while others focus on dosing and side effects. Recent work has expanded past opioid use disorder into post-traumatic stress disorder (PTSD), traumatic brain injury (TBI), alcohol use disorder, and multiple sclerosis (MS). Some study types carry more weight than others, so consider that when deciding how much confidence to place in the results.

Clinical Trials

Clinical trials give participants ibogaine, or a related compound, under a set protocol and then measure what happens. The strongest trials are randomized and placebo-controlled, so neither the patients nor the researchers know who received the real drug. Only a few ibogaine trials meet this standard, and most are in early phases.

Observational Studies

Observational studies follow people who have already chosen ibogaine treatment, often at clinics in Mexico or New Zealand, and measure their outcomes over time. These studies are important because they provide real-world evidence; however, without a control group, it’s harder to rule out other explanations for a patient’s improvement.

Case Reports and Lab Research

Case reports describe one or two patients in detail and often provide the first signal that a treatment deserves closer scrutiny. Lab research studies the molecule itself, including recent work on synthetic ibogaine and new analogs that could carry fewer heart risks in future trials.

Why Do Ibogaine Research Studies Matter?

Research gives patients and providers the scientific foundation needed to weigh ibogaine’s risks against its benefits. Many people already travel abroad for ibogaine treatment for substance use disorders and mental health conditions. Patient reports suggest ibogaine can interrupt addictive patterns and ease withdrawal, but published, peer-reviewed data is what turns those reports into evidence that doctors and regulators can act on.

Clinical trials help determine medical standards, allowing healthcare providers to make informed decisions regarding ibogaine dosage, screening for treatment, and the potential risks associated with treatment. Such standardization can make ibogaine treatment more effective and safer with minimal risks of side effects. These trials broaden our understanding of ibogaine’s potential. They also pave the way for ibogaine, or synthetic forms of it, to be approved by the FDA. This would greatly expand the accessibility of ibogaine treatment throughout North America.

Phases of Clinical Trials

Clinical trials move through a series of phases, each with a distinct purpose. These phases help researchers evaluate a drug’s safety and dosage requirements step by step before approval. Most ibogaine trials to date sit in the earliest phases and test low or gradually increasing doses to limit safety risks. The three main phases are described below.

Phase I Tests Safety and Dosing on a Small Group of Volunteers

Phase I of clinical trials is concerned with dosage safety for the participants. It involves testing the drug for the first time on a small group of healthy volunteers to determine a safe dosage and identify potential side effects. The participants are given a low dose of medication at scheduled intervals. The effects on each participant’s health are carefully monitored by keeping track of the changes they experience while under the medication. Since Phase I clinical trials focus on the medication’s safety, they often involve 10 to 100 volunteers and are not as long as other phases.

Ibogaine studies sometimes break from this model. Because of the compound’s effects on heart rhythm, some early ibogaine and noribogaine trials enroll people who already use opioids. A Phase I/2a study sponsored by atai Therapeutics in the U.K., for example, was designed for about 110 participants, starting with recreational opioid users before moving on to opioid-dependent patients.

Phase II Explores Effectiveness in Patients With Specific Conditions

Phase II of clinical trials aims to study the treatment’s effectiveness in a group of patients with specific conditions. This often involves a larger group of participants, ranging from 100 to 300. Since the primary focus of this phase is to determine the efficacy of the treatment, the trial duration is longer than Phase I and involves extensive data collection. Researchers integrate the dosage guidelines obtained from the Phase I trial and monitor the impact it has on patients’ health conditions. If the outcome shows significant improvement in patients’ health with minimal risk of side effects, the trial is approved for the next phase.

Phase III Confirms Effectiveness and Monitors Side Effects in Large-Scale Studies

Phase III of clinical trials involves large-scale studies to more fully determine the treatment’s effectiveness and side effects. Because it involves studying hundreds or thousands of participants with diverse medical backgrounds and requires extensive testing and analysis, the trial phase is much longer than other phases. This stage also explores the long-term health risks and benefits of the treatment plan. Regulatory agencies like the FDA often depend on Phase III trials to determine whether a treatment is approved for public use.

Purpose of Ibogaine Clinical Trials

Ibogaine clinical trials aim to achieve the following goals:

• Evaluating the safety and efficacy of ibogaine
• Determining standard dosage guidelines for effective treatment
• Understanding the long-term impact of the treatment of various health conditions
• Assessing the psychological effects of ibogaine use
• Investigating ibogaine’s treatment potential for broader medical integration
• Enhancing the accessibility of ibogaine treatment
• Establishing medical approval from regulatory authorities
• Developing synthetic versions and analogs of ibogaine with lower cardiac risk

Key Ibogaine Research Studies and Their Findings

The studies below are some of the most cited ibogaine research to date. They range from patient surveys to a Phase II trial, and read together, they show both ibogaine’s potential and the risks researchers are still working to understand.

1. Subjective effectiveness of ibogaine treatment for problematic opioid consumption (2017): Published in the Journal of Psychedelic Studies, this survey asked 88 people about their experience after ibogaine treatment for opioid use. Of those, 80% said ibogaine eliminated or drastically reduced their withdrawal symptoms, and half reported fewer cravings, with 25% saying the drop in cravings lasted at least 3 months. Close to a third (30%) reported never using opioids again after treatment, while 48% said they used less than before.
2. Magnesium-ibogaine therapy in veterans with traumatic brain injuries (2024): Stanford Medicine researchers led by Dr. Nolan Williams published these findings in Nature Medicine in January 2024. The study followed 30 U.S. special operations veterans with a history of TBI and repeated blast exposure. Each received ibogaine with magnesium, which was added to help prevent heart complications. One month after treatment, participants reported average reductions of 88% in PTSD symptoms, 87% in depression, and 81% in anxiety. Disability scores fell from 30.2 (mild to moderate disability) to 5.1 (no disability), and participants reported no serious side effects or cardiac issues. A follow-up analysis in Nature Mental Health (September 2025) found increased theta brain wave activity after treatment, which researchers have linked to neuroplasticity, the brain’s ability to form new connections.
3. Lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis (2025): This case report, published in Frontiers in Immunology, describes two MS patients treated with ibogaine in Mexico. One patient’s brain lesion shrank by 71% within 3 months, and the second patient went from relying on a wheelchair to walking with support. Brain scans in both patients showed structural changes the authors tied to neuroplasticity. The authors are clear that two case reports can’t prove ibogaine caused these improvements, and they call for controlled trials.
4. Phase II clinical trial with ibogaine for opioid dependency: Run by ICEERS at Sant Joan de Reus Hospital in Spain, this is the first Phase II trial of ibogaine for opioid dependence. It tested low, ascending doses (starting at 100 mg) in 20 people on methadone maintenance. Preliminary results released in January 2025 showed that all participants were able to cut their daily methadone dose by 50% for a week after ibogaine, and no serious adverse events were reported. One participant left the study after a significant increase in their QTc interval, a heart rhythm measurement, and the research team stressed the need for cardiovascular monitoring. This trial used a research-specific protocol. At Experience Ibogaine, patients on methadone or Suboxone first switch to a short-acting opiate for 1 to 2 months before treatment. For methadone patients who make that switch correctly, the program typically lasts about 5 days.
5. Efficient and modular synthesis of ibogaine and related alkaloids (2025): Published in Nature Chemistry in February 2025, this UC Davis study led by Dr. David Olson produced ibogaine in the lab from pyridine in six or seven steps. The team also created new analogs, including one compound that strongly affects neuron growth. Lab synthesis could reduce reliance on harvesting iboga plants and let researchers design versions of the molecule with lower cardiac risk.
6. Observational study of the long-term efficacy of ibogaine-assisted therapy (2017): Sponsored by MAPS and led by Thomas Kingsley Brown and Kenneth Alper, this study followed 30 people with opioid dependence treated at two clinics in Mexico for 12 months. Withdrawal scores fell by more than half within about 3 days of treatment (from 31.0 to 14.0 on the Subjective Opioid Withdrawal Scale). At the 1-month mark, 50% of participants reported no opioid use in the previous 30 days, and improvements in drug use scores held from 3 to 12 months.
7. Ibogaine treatment outcomes for opioid dependence from a 12-month follow-up observational study (2018): This New Zealand study, published in The American Journal of Drug and Alcohol Abuse, tracked 14 people after a single ibogaine treatment. Their drug use scores on the Addiction Severity Index dropped by more than 80% over 12 months (from 0.32 to 0.06). One participant died during treatment, and the coroner concluded the death was very likely related to a cardiac arrhythmia.
8. Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence (2018): Published in Frontiers in Pharmacology by Dr. Deborah Mash and colleagues, this open-label case series covered 191 patients who received ibogaine under inpatient medical monitoring. Ibogaine blocked opioid withdrawal symptoms and reduced drug cravings, and no significant adverse events were reported within the doses tested.
9. Ascending single-dose, placebo-controlled safety study of noribogaine in opioid-dependent patients (2016): Published in Clinical Pharmacology in Drug Development, this double-blind trial gave single doses of noribogaine (ibogaine’s main active metabolite) to 27 patients transitioning off methadone. Noribogaine was well tolerated overall, though the QT interval lengthened as the dose increased, by an average of about 16, 28, and 42 milliseconds at 60, 120, and 180 mg. Withdrawal scores trended lower, especially at 120 mg, but the difference wasn’t statistically significant.

What Research Says About Ibogaine Safety

Safety findings are among the most useful data in the ibogaine literature because they show where risk comes from and how to reduce it.

Heart Rhythm Changes

The most consistent safety concern across ibogaine studies involves the heart. Ibogaine and noribogaine can lengthen the QT interval (the time the heart’s electrical system takes to reset between beats), and a long QT interval raises the risk of dangerous arrhythmias. This effect showed up in the 2016 noribogaine trial and led one participant to leave the ICEERS trial. It was also the suspected cause of the death in the New Zealand study.

What Fatality Reviews Found

A 2012 review in the Journal of Forensic Sciences examined 19 deaths linked to ibogaine between 1990 and 2008. In 12 of the 14 cases with adequate postmortem data, preexisting medical conditions (mainly cardiovascular) or substance use explained or contributed to the death. Seizures tied to alcohol and benzodiazepine withdrawal were flagged as another potential contributing factor, along with the use of unregulated ibogaine products.

How Experience Ibogaine Applies Research to Treatment

Nearly every safety finding above points to the same lesson. Screening and monitoring are what separate a safer ibogaine experience from a risky one, and our protocols are built around that.

Cardiac and Bloodwork Screening

Every patient meets with a cardiologist before treatment. Pre-treatment bloodwork includes a complete liver function test (albumin, total protein, ALP, ALT, AST, GGT, and bilirubin), along with vitamin and electrolyte levels. A urinalysis also screens for drugs that can interact dangerously with ibogaine.

Personalized Dosing and 24/7 Monitoring

We base your dose on your weight, age, substances used, duration of use, liver and heart function, bloodwork, and sensitivity to a test dose, so we never push past the threshold into dangerous territory. Patients receive 24/7 medical supervision in private rooms and go home with two smaller booster doses since only one full dose of ibogaine is safe in a 3- to 4-month period. Continued therapy sessions are also part of aftercare.

An Informed Decision

Our founder, Aeden Aeharn, overcame his own addiction through ibogaine treatment, so our team knows that every number in these studies represents a real person. We want you to read the research and ask yourself the hard questions before you commit. This should be your decision, made with an understanding of the full picture.

Limitations of Current Ibogaine Research

Promising results are a starting point, but the evidence still has gaps. Most ibogaine research shares a few important limitations.

• Small sample sizes: Most studies include anywhere from 2 to 191 participants, far fewer than the thousands typically involved in Phase III trials.
• Few control groups: Observational designs can’t rule out other reasons for improvement, such as a patient’s motivation or the support system around them.
• Self-reported outcomes: Surveys rely on participants’ memory, and people who had positive experiences may be more likely to respond.
• Varied protocols: Doses, screening, and aftercare differ between clinics, which makes results hard to compare.

The Future of Ibogaine Research

Interest in ibogaine research has grown quickly since the Stanford veterans study in 2024. Researchers are developing synthetic analogs designed to lower heart risks, and the early results in TBI and MS have opened new lines of study. In the U.S., the FDA cleared the first in-human testing of a noribogaine formulation in April 2026, which is a step toward the larger randomized trials needed for approval. Ibogaine still has no FDA approval as a treatment, and continued, well-designed research is the path to changing that.

Frequently Asked Questions (FAQs)

References

• Noller et al., American Journal of Drug and Alcohol Abuse (2018)
• Mash et al., Frontiers in Pharmacology (2018)
• Mash et al., Alkaloids: Chemistry and Biology (2001)
• Bouso, José Carlos. “First Results of Ibogaine Research to Reverse Methadone Tolerance.” ICEERS, January 21, 2025.
• Brown, Thomas Kingsley, et al. “Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes.” The American Journal of Drug and Alcohol Abuse, September 11, 2016.
• Chen, David Qixiang, et al. “Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.” Frontiers in Immunology, February 6, 2025.
• Dolan, Eric W. “Ibogaine treatment linked to changes in brain rhythms and psychiatric improvements in veterans with traumatic brain injury.” PsyPost, September 6, 2025.
• Mash, Deborah C., et al. “Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes.” Frontiers in Pharmacology, June 4, 2018.
• Noller, Geoffrey E., et al. “Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.” The American Journal of Drug and Alcohol Abuse, April 12, 2017.
• Watry, Greg. “UC Davis Researchers Achieve Total Synthesis of Ibogaine.” University of California, Davis, February 6, 2025.
• Williams, Sarah. “Psychoactive drug ibogaine effectively treats traumatic brain injury in special ops military vets.” Stanford Medicine, January 5, 2024.